Cancer therapeutics, Stem Cells
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
69
NCT04020575
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 15, 2020
Completion: Jan 15, 2035
Loading map...